Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy

Daniel H. Tewkesbury, Rebecca C. Robey, Peter J. Barry
Breathe 2021 17: 210112; DOI: 10.1183/20734735.0112-2021

Article Information

vol. 17 no. 4
DOI 
https://doi.org/10.1183/20734735.0112-2021
Published By 
European Respiratory Society
Print ISSN 
1810-6838
Online ISSN 
2073-4735
History 
  • Received July 22, 2021
  • Accepted November 9, 2021
  • Published online January 11, 2022.
Copyright & Usage 
Copyright ©ERS 2022 Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

Author Information

  1. Daniel H. Tewkesbury1,2,
  2. Rebecca C. Robey2,3 and
  3. Peter J. Barry1,2⇑
  1. 1Manchester Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
  2. 2Division of Immunology, Immunity to Infection & Respiratory Medicine, University of Manchester, Manchester, UK
  3. 3The North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
  1. Corresponding author: Peter J. Barry (peter.barry{at}mft.nhs.uk)
View Full Text

Article usage

Article usage: January 2022 to February 2023

AbstractFullPdf
Jan 20225436201
Feb 20228398140
Mar 202219384143
Apr 20222113671
May 20221216860
Jun 2022611043
Jul 2022910226
Aug 202298642
Sep 2022311440
Oct 2022610439
Nov 2022112759
Dec 202266123
Jan 20231113721
Feb 2023711139

Altmetrics

Back to top
Email
Print
Citation Tools

Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy
Daniel H. Tewkesbury, Rebecca C. Robey, Peter J. Barry
Breathe Dec 2021, 17 (4) 210112; DOI: 10.1183/20734735.0112-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

Subjects